Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 ...

BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief executive officer saying he would consider a deal with a partner that gets ...

A key enabler for BioNTech's ambitious plans is an exceptionally strong balance sheet, rare for a biotechnology company. As of the end of 2025, the Mainz-based firm reported liquid funds of ...

The independent journey of CureVac on public markets has concluded. The Nasdaq exchange has suspended trading of the company's shares following the finalized ac ...

Strategic collaborations with partners such as Bristol-Myers Squibb and Genentech are intended to accelerate progress. While the pipeline is broadening, management notes that none of the oncology ...